Search company, investor...
Innocoll company logo


Founded Year



Take Private | Alive

Total Raised






About Innocoll

Innocoll is a global commercial stage specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need. The company develops and manufactures a range of surgical implants and topically applied healthcare products using its proprietary collagen based technologies, CollaRx, CollaFilm, CollaPress and LiquiColl.

Headquarters Location

Unit 9, Block D Monksland Business Park



+353 (0)90 648 6834

Missing: Innocoll's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Innocoll's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Innocoll

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Innocoll is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Innocoll Patents

Innocoll has filed 1 patent.

The 3 most popular patent topics include:

  • Collagens
  • Polysaccharides
  • Carbohydrates
patents chart

Application Date

Grant Date


Related Topics




Calcium channel blockers, Piperidines, Analgesics, Amines, Anesthesia


Application Date


Grant Date



Related Topics

Calcium channel blockers, Piperidines, Analgesics, Amines, Anesthesia



Latest Innocoll News

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs - Durect (NASDAQ:D

Nov 2, 2022

- AHFIRM trial timeline continues to improve CUPERTINO, Calif., Nov. 2, 2022 /PRNewswire / -- DURECT Corporation DRRX today announced financial results for the three months ended September 30, 2022 and provided a corporate update. We are excited that we are now on track to complete enrollment of our pivotal AHFIRM trial in the second quarter of 2023, earlier than we previously estimated. We continue to make excellent progress toward our goal of bringing larsucosterol to market as the first FDA-approved treatment for alcohol-associated hepatitis, stated James E. Brown, D.V.M., President and CEO of DURECT. In addition, we earned $10 million in total milestone payments from our Innocoll collaboration. We are pleased that Innocoll has launched POSIMIR and look forward to following their launch progress. AD Third Quarter and Recent Business Highlights: Continued progress in AHFIRM enrollment DURECT has enrolled more than 200 patients in the AHFIRM trial to date, which exceeds two-thirds of the target enrollment for the 300-patient trial. We have over 60 AHFIRM study sites open at leading hospitals in the U.S., Australia, E.U. and U.K. and are continuing to open new sites, including prominent transplant centers. We currently expect to complete enrollment in the AHFIRM trial in the second quarter of 2023, which should enable top-line results to be reported in the second half of 2023. Commercial launch of POSIMIR In September 2022, Innocoll Pharmaceuticals Limited (Innocoll) commercially launched and achieved the first sales of POSIMIR in the United States, triggering a $2 million milestone for DURECT. In August 2022, DURECT was issued a new patent by the US Patent Office, extending US patent coverage for POSIMIR to at least 2041. This event triggered an $8 million milestone payment which was received by DURECT during the third quarter. Financial Highlights for Q3 2022:

Innocoll Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Innocoll Rank

Innocoll Frequently Asked Questions (FAQ)

  • When was Innocoll founded?

    Innocoll was founded in 1985.

  • Where is Innocoll's headquarters?

    Innocoll's headquarters is located at Unit 9, Block D, Athlone.

  • What is Innocoll's latest funding round?

    Innocoll's latest funding round is Take Private.

  • How much did Innocoll raise?

    Innocoll raised a total of $31.31M.

  • Who are the investors of Innocoll?

    Investors of Innocoll include Gurnet Point Capital, NewSmith Asset Management, Camulos Capital and Morgan Stanley.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.